Acute phase reactant proteins in prostatic cancer.
A profile of acute phase reactant proteins has been studied in patients with cancer of the prostate as an aid to diagnostic staging and therapy control. A linear discriminant function analysis incorporating serum acid phosphatase, prealbumin, alpha1 antitrypsin, alpha1 acid glycoprotein and haptoglobin allows the correct identification of metastatic disease in 88.6% of patients. The profile may also serve to augment other parameters in the assessment of the physiological effect of oestrogen treatment and show whether the prescribed medication is being taken.
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000510:Alpha-Globulins / Q000032:analysis*; D002570:Ceruloplasmin / Q000032:analysis; D004967:Estrogens / Q000494:pharmacology* / Q000627:therapeutic use; D006023:Glycoproteins / Q000097:blood; D006242:Haptoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011228:Prealbumin / Q000032:analysis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy; D011506:Proteins / Q000032:analysis*; D000515:alpha 1-Antitrypsin / Q000032:analysis
D000510:Alpha-Globulins; D004967:Estrogens; D006023:Glycoproteins; D006242:Haptoglobins; D011228:Prealbumin; D011506:Proteins; D000515:alpha 1-Antitrypsin; D002570:Ceruloplasmin; D000135:Acid Phosphatase